Reports


Global Proteasome Inhibitors for Multiple Myeloma Market 2020-2029 (By By PD-1 Inhibitor(Bortezomib, Carfilzomib, Ixazomib ) By Route (Powder for solution , Injection powder , Lyophilized for solution, Injection powder for solution, Capsule))

  • TBI236758
  • September 27, 2020
  • Global
  • 139 pages
  • TSCIR
                                              Abstract, Snapshot, Market Analysis & Market Definition: Global Proteasome Inhibitors for Multiple Myeloma Market

In 2020, the global Proteasome Inhibitors for Multiple Myeloma market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2029. This report focuses on the global Proteasome Inhibitors for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Proteasome Inhibitors for Multiple Myeloma development in United States, Europe and China.

Market Segmentation, Outlook & Viewpoint: Global Proteasome Inhibitors for Multiple Myeloma Market

Segmentation by Route Type: Breakdown of data from year 2014 to 2019 and forecast until 2029:
  • Powder
  • Injection
  • lyophilized
  • Solution
  • Capsule
Segmentation by Product Type: Breakdown of data from year 2014 to 2019 and forecast until 2029:
  • Bortezomib
  • Carfilzomib
  • Ixazomib
  • Other
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. It is a reversible inhibitor of the 26S proteasome, which is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway. Inhibition of 26S proteasome leads to cell cycle arrest and apoptosis of cancer cells. While inhibition of the 26S proteasome is the main mechanism of action, multiple mechanisms may involved in the therapeutic action of bortezomib. Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved on July 20, 2012. Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. Segmentation by Application : Breakdown of data from year 2014 to 2019 and forecast until 2029:
  • Hospital
  • Drug Center
  • Clinic
  • Other
Top Companies & Key Players: Global Proteasome Inhibitors for Multiple Myeloma Market
  • Millennium Pharmaceuticals, Inc.
  • Takeda
  • Onyx Pharmaceuticals, Inc.
  • Amgen
  • Actavis Pharma Company
  • Fresenius Kabi USA, LLC
  • Apotex Corporation
  • Dr.Reddy's Laboratories Inc
  • TEVA Canada Limited
  • Pfizer Canada Ulc
  • Juno Pharmaceuticals Corp.
  • Sandoz Canada Incorporated
  • Janssen Cilag International Nv
In Aug 2020, US FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens. Amgen (NASDAQ:AMGN) announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd) in two dosing regimens — once weekly and twice weekly — for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received one to three previous lines of therapy. Multiple myeloma is a blood cancer characterized by patterns of remission and relapse. Patient outcomes worsen with each relapse. With the increasing use of frontline immunomodulatory drug based (IMiD) therapies through progression, the number of patients treated with these agents who will progress is likely to increase with time. This creates an emerging need for efficacious lMiD-free regimens upon relapse. The DKd regimen provides an important potent triplet option in the setting of relapse following IMiD combination frontline therapy Key Insights Covered: Global Proteasome Inhibitors for Multiple Myeloma Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Proteasome Inhibitors for Multiple Myeloma industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Proteasome Inhibitors for Multiple Myeloma industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Proteasome Inhibitors for Multiple Myeloma industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Proteasome Inhibitors for Multiple Myeloma industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Proteasome Inhibitors for Multiple Myeloma industry. Research Methodology: Global Proteasome Inhibitors for Multiple Myeloma Market
  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.


1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type

1.4.1 Global Proteasome Inhibitors for Multiple Myeloma Market Size Growth Rate by Type (2014-2025)

1.4.2 Bortezomib

1.4.3 Carfilzomib

1.4.4 Ixazomib 

1.4.5 Other
1.5 Market by Application

1.5.1 Global Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2014-2025)

1.5.2 Hospital

1.5.3 Drug Center

1.5.4 Clinic

1.5.5 Other
1.6 Study Objectives
1.7 Years Considered2 Global Growth Trends
2.1 Proteasome Inhibitors for Multiple Myeloma Market Size
2.2 Proteasome Inhibitors for Multiple Myeloma Growth Trends by Regions

2.2.1 Proteasome Inhibitors for Multiple Myeloma Market Size by Regions (2014-2025)

2.2.2 Proteasome Inhibitors for Multiple Myeloma Market Share by Regions (2014-2019)
2.3 Industry Trends

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Opportunities3 Market Share by Key Players
3.1 Proteasome Inhibitors for Multiple Myeloma Market Size by Manufacturers

3.1.1 Global Proteasome Inhibitors for Multiple Myeloma Revenue by Manufacturers (2014-2019)

3.1.2 Global Proteasome Inhibitors for Multiple Myeloma Revenue Market Share by Manufacturers (2014-2019)

3.1.3 Global Proteasome Inhibitors for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.2 Proteasome Inhibitors for Multiple Myeloma Key Players Head office and Area Served
3.3 Key Players Proteasome Inhibitors for Multiple Myeloma Product/Solution/Service
3.4 Date of Enter into Proteasome Inhibitors for Multiple Myeloma Market
3.5 Mergers & Acquisitions, Expansion Plans4 Breakdown Data by Type and Application
4.1 Global Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2014-2019)
4.2 Global Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2014-2019)5 United States
5.1 United States Proteasome Inhibitors for Multiple Myeloma Market Size (2014-2019)
5.2 Proteasome Inhibitors for Multiple Myeloma Key Players in United States
5.3 United States Proteasome Inhibitors for Multiple Myeloma Market Size by Type
5.4 United States Proteasome Inhibitors for Multiple Myeloma Market Size by Application6 Europe
6.1 Europe Proteasome Inhibitors for Multiple Myeloma Market Size (2014-2019)
6.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Europe
6.3 Europe Proteasome Inhibitors for Multiple Myeloma Market Size by Type
6.4 Europe Proteasome Inhibitors for Multiple Myeloma Market Size by Application7 China
7.1 China Proteasome Inhibitors for Multiple Myeloma Market Size (2014-2019)
7.2 Proteasome Inhibitors for Multiple Myeloma Key Players in China
7.3 China Proteasome Inhibitors for Multiple Myeloma Market Size by Type
7.4 China Proteasome Inhibitors for Multiple Myeloma Market Size by Application8 Japan
8.1 Japan Proteasome Inhibitors for Multiple Myeloma Market Size (2014-2019)
8.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Japan
8.3 Japan Proteasome Inhibitors for Multiple Myeloma Market Size by Type
8.4 Japan Proteasome Inhibitors for Multiple Myeloma Market Size by Application9 Southeast Asia
9.1 Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size (2014-2019)
9.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Southeast Asia
9.3 Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size by Type
9.4 Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size by Application10 India
10.1 India Proteasome Inhibitors for Multiple Myeloma Market Size (2014-2019)
10.2 Proteasome Inhibitors for Multiple Myeloma Key Players in India
10.3 India Proteasome Inhibitors for Multiple Myeloma Market Size by Type
10.4 India Proteasome ...
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form